Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan:292:114620.
doi: 10.1016/j.socscimed.2021.114620. Epub 2021 Dec 1.

The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment

Shana D Stites  1 , Jeanine Gill  2 , Emily A Largent  3 , Kristin Harkins  2 , Pamela Sankar  4 , Abba Krieger  5 , Jason Karlawish  6
Affiliations
Randomized Controlled Trial

The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment

Shana D Stites et al. Soc Sci Med. 2022 Jan.

Abstract

Objective: The symptoms and prognosis of Alzheimer's disease (AD) dementia contribute to the public's negative reactions toward individuals with AD dementia and their families. But what if, using AD biomarker tests, diagnosis was made before the onset of dementia, and a disease-modifying treatment was available? This study tests the hypotheses that a "preclinical" diagnosis of AD and treatment that improves prognosis will mitigate stigmatizing reactions.

Methods: A sample of U.S. adults were randomized to receive one vignette created by a 3 × 2 × 2 vignette-based experiment that described a person with varied clinical symptom severity (Clinical Dementia Rating stages 0 (no dementia), 1 (mild), or 2 (moderate)), AD biomarker test results (positive vs negative), and disease-modifying treatment (available vs not available). Between-group comparisons were conducted of scores on the Modified Family Stigma in Alzheimer's Disease Scale (FS-ADS).

Results: The sample of 1,817 adults had a mean age two years younger than that of U.S. adults but was otherwise similar to the general adult population. The response rate was 63% and the completion rate was 96%. In comparisons of randomized groups, mild and moderate symptoms of dementia evoked stronger reactions on all FS-ADS domains compared to no dementia (all p < 0.001). A positive biomarker test result evoked stronger reactions on all but one FS-ADS domain (negative aesthetic attributions) compared to a negative biomarker result (all p < 0.001). Disease-modifying treatment had no measurable influence on stigma (all p > 0.05).

Conclusions: The stigmas of dementia spill over into preclinical AD, and availability of treatment does not alter that stigma. Translation of the preclinical AD construct from research into practice will require interventions that mitigate AD stigma to preserve the dignity and identity of individuals living with AD.

Keywords: Alzheimer's biomarkers; Preclinical Alzheimer's; Stigma; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts

The authors have no conflicts to disclose.

Figures

Figure 1.
Figure 1.
Consort Diagram: Study flow through analysis Note. The comprehension item confirmed respondents accurately understood the educational information on use of Alzheimer’s disease biomarkers. Respondents were given two opportunities to select the correct choice. Those who failed on the second attempt were excluded. *Demographic quota – Population-based allocations were used for race, ethnicity, gender, education achievement.
Figure 2.
Figure 2.
Box plot of domain distributions on Family Stigma in Alzheimer’s Disease Scale (FS-ADS) by biomarker test result. Neg. = A negative Alzheimer’s disease biomarker test. Pos. = A positive Alzheimer’s disease biomarker test. Legend: point = outlier, defined as a value more than 1.5 times the lower or upper quartile; upper and lower whiskers = maximum and minimum values, respectively, excluding outliers; top and bottom of rectangle = upper and lower quartiles, respectively; and white horizontal line = median value.
See this image and copyright information in PMC

References

    1. Alzheimer’s Association National Plan Milestone Workgroup, Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, Kukull WA, Lamb B, Logsdon RG, Maruff P, Mesulam M, Mobley W, Mohs R, Morgan D, Nixon RA, Paul S, Petersen R, Plassman B, Potter W, Reiman E, Reisberg B, Sano M, Schindler R, Schneider LS, Snyder PJ, Sperling RA, Yaffe K, Bain LJ, Thies WH, Carrillo MC, 2014. 2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease. Alzheimers Dement 10, S430–452. 10.1016/j.jalz.2014.08.103 - DOI - PubMed
    1. Alzheimer’s vaccine shows promise in Phase II trial, n.d.. European Pharmaceutical Review. URL https://www.europeanpharmaceuticalreview.com/news/156676/alzheimers-vacc... (accessed 10.29.21).
    1. American Community Survey (ACS) [WWW Document], n.d. The United States Census Bureau. URL https://www.census.gov/programs-surveys/acs (accessed 4.28.20).
    1. Anderson LA, Egge R, 2014. Expanding efforts to address Alzheimer’s disease: The Healthy Brain Initiative. Alzheimers Dement 10, S453–S456. 10.1016/j.jalz.2014.05.1748 - DOI - PMC - PubMed
    1. Arias JJ, Tyler AM, Oster BJ, Karlawish J, 2018. The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer’s Disease Biomarkers. J. Law. Med. Ethics 46, 485–498. 10.1177/1073110518782955 - DOI - PubMed

Publication types